Ivoximab 20 mg/kg, ivgtt, Q4W + Temozolomide for glioma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 10 Oct 2024: Trial started, NCT07599371
  2. 20 May 2026: Trial registered, NCT07599371

The trials

NCT07599371: A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma

State
Under way
Phase
Phase 1 and Phase 2
People
29 planned
Started
10 Oct 2024
Primary completion
10 Oct 2027
Arms
ivoximab combined with temozolomide
Results
None posted
  1. 10 Oct 2024: Trial started
  2. 20 May 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.